IMS Health Holdings (NYSE:IMS) : 5 brokerage houses believe that IMS Health Holdings (NYSE:IMS) is a Strong Buy at current levels. 4 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on IMS Health Holdings (NYSE:IMS). Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 9 Wall Street Analysts endorse the stock as a Buy with a rating of 1.89.
IMS Health Holdings (NYSE:IMS) : The most positive equity analysts on IMS Health Holdings (NYSE:IMS) expects the shares to touch $38, whereas, the least positive believes that the stock will trade at $26 in the short term. The company is covered by 8 Wall Street Brokerage Firms. The average price target for shares are $32.13 with an expected fluctuation of $3.64 from the mean.
For the current week, the company shares have a recommendation consensus of Buy. Also, Wells Fargo downgrades their rating on the shares of IMS Health Holdings (NYSE:IMS). The current rating of the shares is Market Perform. Earlier, the shares were rated a Outperform by the brokerage firm. The rating by the firm was issued on May 12, 2016.
IMS Health Holdings (NYSE:IMS): stock turned positive on Tuesday. Though the stock opened at $23.88, the bulls momentum made the stock top out at $24.2 level for the day. The stock recorded a low of $23.85 and closed the trading day at $24.18, in the green by 1.94%. The total traded volume for the day was 932,046. The stock had closed at $23.72 in the previous days trading.
In an insider trading activity, The Securities and Exchange Commission has divulged that Knightly Kevin C, officer (SVP, Information Offerings) of Ims Health Holdings, Inc., had unloaded 19,231 shares at an average price of $28.5 in a transaction dated on November 23, 2015. The total value of the transaction was worth $548,084.
IMS Health Holdings, Inc. (IMS) is an information and technology services company that provides solutions to its clients in the healthcare industry. The Company has its presence in over 100 countries. The Companys data set contains over 10 petabytes of data and over 500 million patient records. The Company serves healthcare organizations and life science companies, including pharmaceutical, biotechnology, consumer health and medical device manufacturers, as well as distributors, providers, payers, government agencies, policymakers, researchers and the financial community. The Companys principal offerings include national information offerings, sub-national information offerings, workflow analytics, real-world evidence (RWE) solutions, technology and applications and clinical solutions.